Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success
NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical...
Day: July 18, 2024
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine...
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to...
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
SANTA ANA, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD)VOQUEZNA met its primary endpoint...
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company,...
Inovalon’s Converged Quality Achieves 24th Consecutive NCQA HEDIS® Certification
The Company’s Solutions are Trusted by the Health Plans Representing 80% of all U.S. Covered Lives to Deliver HEDIS Results...
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company...
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable...
OPKO Health Announces $100 Million Share Repurchase Program
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has...
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data...
HealthyMD and IMG Health Clinic Unite to Advance Health Equity and Access to Care for 50M+ Underserved People Across the U.S.
Groundbreaking hybrid care model elevates standard of care for sexual healthcare of underserved populations, improves quality of life, and strengthens...
CareTalk Health Revolutionizes Healthcare by Launching First Clinical Process Outsourcing Company Nationwide
With the ability to bill Medicare in all 50 states, CareTalk Health offers licensed physicians and clinicians in every state,...
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
Science 37 Supports Phase 3 Clinical Trial with Recruitment and Enrollment, Enhancing Access for Immunocompromised Patients Across the U.S.MORRISVILLE, N.C.,...
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or...
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar...
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-ToleratedLargest Clinical Data Set in Pneumonia for Any...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic...